2. Search Result
Search Result
Results for "

Diphosphorylated myosin light chain

" in MedChemExpress (MCE) Product Catalog:

2668

Inhibitors & Agonists

9

Bibliotecas de Screening

119

Fluorescent Dyes

586

Biochemical Assay Reagents

159

Peptides

11

MCE Kits

362

Inhibitory Antibodies

304

Natural
Products

301

Recombinant Proteins

213

Isotope-Labeled Compounds

358

Antibodies

98

Click Chemistry

106

Oligonucleotides

2

GMP Molecules

Targets Recommended:
Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-139465
    Aficamten
    3 Publications Verification

    CK-274; CK-3773274

    		 Myosin Cardiovascular Disease
    Aficamten (CK-274) is a potent cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM) .
    Aficamten
  • HY-132580
    Tofersen
    2 Publications Verification

    BIIB067; ISIS-SOD1Rx; ISIS 333611

    		 SOD Neurological Disease
    Tofersen (BIIB067) is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis .
    Tofersen
  • HY-148799
    Sevasemten

    EDG-5506

    		 Myosin Others
    Sevasemten is an orally active, selective allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten decreases muscle damage biomarkers and fibrosis while increasing muscle strength and activity in in Duchenne muscular dystrophy disease models .
    Sevasemten
  • HY-B0754A
    Hematoporphyrin dihydrochloride
    10+ Cited Publications

    Hematoporphyrin IX dihydrochloride

    		 Apoptosis Endogenous Metabolite Cancer
    Hematoporphyrin dihydrochloride (Hematoporphyrin IX dihydrochloride), a photosensitizer, is a substrate for affinity chromatography of heme-binding proteins. Hematoporphyrin dihydrochloride can induce apoptosis in U87 glioma cells and decrease tumor growth in vivo when exposed to red light .
    Hematoporphyrin dihydrochloride
  • HY-100912
    W-7 hydrochloride
    5+ Cited Publications

    		 Phosphodiesterase (PDE) Myosin Apoptosis Calmodulin Potassium Channel Cancer
    W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca 2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 hydrochloride induces apoptosis and has antitumor and vascular relaxing activity. W-7 hydrochloride is a blocker of Kv4.3 and can be used for research of arrhythmias .
    W-7 hydrochloride
  • HY-P3479
    Insulin (swine)

    		Insulin Receptor Metabolic Disease
    Insulin (swine) is an orally active insulin derived from pigs. Insulin (swine) when administered orally acts as an antigen to reduce the severity of pancreatic lymphocyte infiltration, but has no metabolic effect on blood glucose levels. Insulin (swine) increases glucose oxidation, stimulates lipogenesis, and lowers blood glucose levels. Insulin (swine) can be used in diabetes research .
    Insulin (swine)
  • HY-Y0413
    Biacetyl monoxime

    Diacetyl monoxime; DAM

    		 Na+/K+ ATPase Myosin Cardiovascular Disease Metabolic Disease
    Biacetyl monoxime (Diacetyl monoxime), a myosin ATPase inhibitor, is a skeletal and cardiac muscle contraction inhibitor. Biacetyl monoxime is also a well-characterized non-competitive inhibitor of chemical and motile activity of skeletal muscle myosin-II. Biacetyl monoxime induces sarcoplasmic reticulum Ca 2+ release .
    Biacetyl monoxime
  • HY-16690
    BTS
    3 Publications Verification

    N-Benzyl-p-toluenesulfonamide; N-Tosylbenzylamine

    		 Myosin Others
    BTS (N-Benzyl-p-toluenesulfonamide) is a potent and selective inhibitor of skeletal muscle myosin II subfragment 1 (S1) ATPase activity, with an IC50s of ~5 µM for actin- and Ca 2+-stimulated myosin S1 ATPase. BTS specifically inhibits the contraction of fast skeletal muscle fibers .
    BTS
  • HY-100932
    ML-9
    5 Publications Verification

    		 Myosin Cancer
    ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively . ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation .
    ML-9
  • HY-D1416
    HMBR
    1 Publications Verification

    		 Fluorescent Dye Others
    HMBR is an analogue with an additional methyl group on the aromatic ring and is non-fluorescent. HMBR conjugated with Y-FAST emits yellow fluorescence under blue light excitation (Ex= 419 nm; Em= 525–539 nm). HMBR is non-toxic to zebrafish embryos. HMBR has high cell permeability .
    HMBR
  • HY-P99481
    Birtamimab

    NEOD001

    		 Amyloid-β Neurological Disease
    Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .
    Birtamimab
  • HY-159821
    Ulacamten

    CK-4021586; CK-586

    		 Myosin Cardiovascular Disease
    Ulacamten (CK-4021586; CK-586) is an orally active cardiac myosin inhibitor and an inhibitor of the double-headed cardiac heavy meromyosin (HMM)ATPase (excluding single-headed myosin subfragment-1), with an EC50 of 2.9 μM. Ulacamten regulates cardiac myosin, reduces excessive myocardial contractility, and alleviates left ventricular outflow tract obstruction. Ulacamten increases the left ventricular short-axis systolic internal diameter, inhibits dobutamine-induced exacerbation of obstruction, and exerts only a mild reducing effect on left ventricular systolic function. Ulacamten also inhibits the fractional shortening of the short axis without altering calcium transients. Ulacamten shows good safety and tolerability in purpose-bred cats with naturally occurring obstructive hypertrophic cardiomyopathy .
    Ulacamten
  • HY-148516
    MPH-220
    1 Publications Verification

    		 Myosin Neurological Disease
    MPH-220 is a selective and orally active inhibitor of skeletal muscle myosin-2. MPH-220 enables muscle relaxation. MPH-220 is anti-spastic agent that can be used in the research of spasticity and muscle stiffness .
    MPH-220
  • HY-175199
    MT-228

    BPN-0026709

    		 Myosin Neurological Disease
    MT-228 (BPN-0026709) is a selective and blood-brain barrier permeable non-muscle myosin II inhibitor. MT-228 markedly improves tolerability by selectively targeting NMIIB (KI = 1.5 μM) over CMII (KI = 17 μM), and the sequence of SmMll MD is 83.6% identical to that of NMllB. MT-228 shows long-lasting efficacy in animal models of stimulant use disorder .
    MT-228
  • HY-P99810
    Quisovalimab

    AVTX-002; AEVI 002; SAR 252067; CERC-002; MDGN-002

    		 SARS-CoV Infection Inflammation/Immunology
    Quisovalimab (AVTX-002) is a human-derived monoclonal antibody against LIGHT (TNFSF14). Quisovalimab binds to LIGHT, blocks the signal transduction activity of LIGHT, reduces circulating LIGHT levels and attenuates pro-inflammatory effects. Quisovalimab can be used in research related to Crohn's disease, COVID-19-associated pneumonia and acute respiratory distress syndrome comorbidity .
    Quisovalimab
  • HY-175188
    MT-110

    BPN-0027490

    		 Myosin Neurological Disease
    MT-110 (BPN-0027490) is a non-muscle myosin NMIIB-selective inhibitor with high brain penetration and favorable safety profile. MT-110 specifically disrupts NMIIB-dependent actin dynamics in dendritic spines, while it exerts no significant adverse effects on cardiac myosin II and cardiac functions (such as cardiac output and heart rate) at tested concentrations. A single administration of MT-110 produces long-lasting (sustained for several weeks) blockade of methamphetamine motivation associated with environmental cues. MT-110 exhibits extremely high specificity, with no interference with cocaine motivation, hippocampus-dependent memory, fear memory, or locomotor and anxiety-like behaviors. MT-110 serves as a valuable tool compound for investigating the mechanisms of methamphetamine use disorder .
    MT-110
  • HY-114367
    Delphinidin 3-rutinoside chloride
    1 Publications Verification

    Delphinidin 3-O-rutinoside chloride

    		 Endothelin Receptor NO Synthase Myosin GLP Receptor Neurological Disease Metabolic Disease
    Delphinidin 3-rutinoside chloride is an anthocyanin component. Delphinidin 3-rutinoside chloride is isolable from the fruits of blackcurrant Ribes nigrum L. Delphinidin 3-rutinoside chloride activates the ETB receptor and stimulates the NO/cGMP pathway. Delphinidin 3-rutinoside chloride increases cyclic guanosine monophosphate production and reduces the phosphorylation level of Myosin regulatory light chain. Delphinidin 3-rutinoside chloride stimulates GLP-1 secretion. It significantly induces relaxation of bovine ciliary muscle strips contracted by ET-1 and inhibits ET-1-induced contraction of bovine ciliary muscle strips. Delphinidin 3-rutinoside chloride is applicable to research related to type 2 diabetes .
    Delphinidin 3-rutinoside chloride
  • HY-126367
    Light green SF yellowish
    1 Publications Verification

    Acid Green 5

    		 Fluorescent Dye Cancer
    Light green SF yellowish (Acid Green 5) is a water-soluble triarylmethane dye. Light green SF yellowish serves as a histological stain that selectively labels mitochondria, collagen, and cartilage, while being an essential component of Papanicolaou staining. Light green SF yellowish is commonly used as a cytoplasmic counterstain for nuclear stains, and is applied in Masson's trichrome staining for collagen fibers, Pap staining, and cytological polychromatic staining in histopathology. Light green SF yellowish also induces growth inhibition and local fibrosarcomas in rats and exerts mild pulmonary tumorigenicity in mice .
    Light green SF yellowish
  • HY-B1556
    Benzyl salicylate

    NSC 6647

    		 Environmental Pollutants Apoptosis Drug Derivative p38 MAPK ERK JNK Cancer
    Benzyl salicylate (NSC 6647)?is a salicylic acid benzyl ester. It can be used as a fragrance additive or UV light absorber .
    Benzyl salicylate
  • HY-B0754
    Hematoporphyrin

    Hematoporphyrin IX

    		 Apoptosis Endogenous Metabolite Cancer
    Hematoporphyrin (Hematoporphyrin IX), a photosensitizer, is a substrate for affinity chromatography of heme-binding proteins. Hematoporphyrin can induce apoptosis in U87 glioma cells and decrease tumor growth in vivo when exposed to red light .
    Hematoporphyrin
  • HY-P990785
    Etentamig

    ABBV-383; TNB 383B

    		 CD3 Cardiovascular Disease Inflammation/Immunology Cancer
    Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .
    Etentamig
  • HY-P991699
    Lixarkitug

    AZD9829 antibody; INT-020

    		 ADC Antibody Interleukin Related Cancer
    Lixarkitug (AZD9829 antibody; INT-020) is a humanized IgG1κ antibody targeting IL-3Ra/CD123. Lixarkitug can be conjugated with Samrotecan to form the intact ADC molecule lixarkitug samrotecan (AZD9829), which is used in studies of acute myeloid leukemia (AML) . The isotype control corresponding to Lixarkitug is Human IgG1 kappa, Isotype Control (HY-P99001).
    Lixarkitug
  • HY-126236
    3,5-Diiodothyropropionic acid
    1 Publications Verification

    		 Thyroid Hormone Receptor Cardiovascular Disease Endocrinology
    3,5-Diiodothyropropionic acid is a thyroid hormone analog, induces α-myosin heavy chain mRNA expression, binds to thyroid hormone receptor (TR), with Ka of 2.40 and 4.06 M -1 for TRα1 and TRβ1, respectively. 3,5-Diiodothyropropionic acid promotes angiogenesis in 3-D human dermal microvascular endothelial cell sprouting assay. 3,5-Diiodothyropropionic acid prevents myocardial arteriolar loss in thyroidectomized rats and enhances cardiac energy-generating capacity in postinfarction heart failure rats. 3,5-Diiodothyropropionic can be used in studies related to angiogenesis and heart failure .
    3,5-Diiodothyropropionic acid
  • HY-152949
    Myosin V-IN-1

    		Myosin Neurological Disease
    Myosin V-IN-1 (compound 8) is a potent and selective Myosin V inhibitor, with a Ki of 6 μM. Myosin V-IN-1 shows acute inhibition of myosin V. Myosin V-IN-1 slows the actin-activated myosin V ATPase by specifically inhibiting ADP release from the actomyosin complex .
    Myosin V-IN-1
  • HY-P1029
    MLCK inhibitor peptide 18
    5+ Cited Publications

    		 Myosin CaMK Autophagy Others
    MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.
    MLCK inhibitor peptide 18
  • HY-P3432
    DfTat

    		Biochemical Assay Reagents Others
    DfTat is a dimer of the prototypical cell-penetrating peptide TAT. DfTat can deliver small molecules, peptides and proteins into live cells with a particularly high efficiency. DfTat labeled with the rhodamine can be used as a tracer for easy detection .
    DfTat
  • HY-P1805
    Calmodulin Binding Peptide 1

    		Calmodulin Neurological Disease
    Calmodulin Binding Peptide 1 is a high-affinity (pM) CaM-binding peptide derived from smooth muscle myosin light chain kinase (MLCK peptide). The interface of the complex formed by Calmodulin Binding Peptide 1 and Ca 2+-CaM can be specifically bound by small-molecule inhibitors, serving as a key target for selective regulation of smooth muscle contraction and development of anti-CaM drugs .
    Calmodulin Binding Peptide 1
  • HY-131618
    Hippuryl-Arg

    Bz-Gly-Arg

    		 Amino Acid Derivatives Others
    Hippuryl-Arg (Bz-Gly-Arg) is a substrate used for fluorescence detection and is commonly used in biochemical studies, especially in studying enzyme activity. The phenylalanine portion of Hippuryl-Arg is connected by an aromatic side chain, which allows it to be detected under ultraviolet light. Hippuryl-Arg is used to detect enzymes that recognize and cut peptide bonds containing arginine .
    Hippuryl-Arg
  • HY-107657
    (+)-Blebbistatin
    1 Publications Verification

    		 Myosin Others
    (+)-Blebbistatin is the inactive enantiomer of (–)-Blebbistatin. (–)-Blebbistatin is a selective inhibitor of myosin II ATPase .
    (+)-Blebbistatin
  • HY-116420
    ROCK2-IN-8

    		ROCK Neurological Disease
    ROCK2-IN-8 (Compound 1) is an orally active ROCK2 inhibitor, with an IC50 of 7.2 nM. ROCK2-IN-8 can be used for the research of aqueous humor outflow in porcine eyes and myosin light chain phosphorylation .
    ROCK2-IN-8
  • HY-140341A
    Sulfo-NHS-Acetate sodium

    		PROTAC Linkers Others
    Sulfo-NHS-Acetate sodium is an alkyl chain-based PROTAC linker. Sulfo-NHS-Acetate sodium can be used in the synthesis of PROTACs .
    Sulfo-NHS-Acetate sodium
  • HY-N9625
    Violaxanthin

    		Photosystem II Others
    Violaxanthin is a lipophilic epoxy carotenoid and a light energy scavenger with biological activities such as antioxidation and anti-inflammation. Violaxanthin exists in photosynthetic eukaryotes including higher plants and participates in the xanthophyll cycle. As a component of the xanthophyll cycle, violaxanthin can be synthesized from zeaxanthin under the catalysis of epoxidase and scavenge excess light energy in photosynthetic eukaryotes .
    Violaxanthin
  • HY-169183
    Myokinasib-II

    		Myosin Cancer
    Myokinasib-II is a myosin light chain kinase (MLCK) inhibitor, which is a potential target for inflammatory diseases, cancer and other diseases. .
    Myokinasib-II
  • HY-120997
    E6 Berbamine

    Berbamine p-nitrobenzoate

    		 Calmodulin Myosin Phosphodiesterase (PDE) Cardiovascular Disease Cancer
    E6 Berbamine (Berbamine p-nitrobenzoate) is a potent calmodulin (CaM) antagonist. E6 Berbamine inhibits the activities of calmodulin-dependent myosin light chain kinase (MLCK) and phosphodiesterase (PDE). E6 Berbamine exhibits anti-leukemic activity. E6 Berbamine can be used in research related to cardiovascular abnormalities and chronic myeloid leukemia .
    E6 Berbamine
  • HY-130368
    W-7
    5+ Cited Publications

    		 Calmodulin Potassium Channel Phosphodiesterase (PDE) Myosin Apoptosis Cardiovascular Disease
    W-7 is a selective calmodulin antagonist. W-7 inhibits the Ca 2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 induces apoptosis and has antitumor and vascular relaxing activity. W-7 is a blocker of Kv4.3 and can be used for research of arrhythmias .
    W-7
  • HY-154636A
    Light Liquid Paraffin

    		Biochemical Assay Reagents Others
    Light Liquid Paraffin can be used as an excipient, such as excipient, lubricant. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs .
    Light Liquid Paraffin
  • HY-161092
    KIO-301 chloride

    		HCN Channel Potassium Channel Neurological Disease
    KIO-301 chloride is an azobenzene photoswitch compound that can block voltage-gated ion channels, including hyperpolarisation-activated cyclic nucleotide-gated (HCN) and voltage-gated potassium channels during exposure to visible light .
    KIO-301 chloride
  • HY-163120
    Myosin-IN-1

    		Myosin Cardiovascular Disease
    Myosin-IN-1 (compound F10) is a Myosin inhibitor that specifically targets cardiac myosin. Myosin-IN-1 stabilizes the biochemical and structural closed state of the cardiac myosin motor domain and reduces myocardial force production and calcium sensitivity in vitro. Myosin-IN-1 acts as a negative inotropic agent in isolated Langendroff-perfused rat hearts, reducing stress in isolated myofilaments and left ventricular pressure development. Myosin-IN-1 can be used in heart failure research .
    Myosin-IN-1
  • HY-161092A
    KIO-301 chloride hydrochloride

    		HCN Channel Potassium Channel Neurological Disease
    KIO-301 chloride hydrochloride is an azobenzene photoswitchable compound that blocks voltage-gated ion channels, including hyperpolarization-activated cyclic nucleotide gating (HCN, during exposure to visible light) ) and voltage-gated potassium channels (voltage-gated potassium channels) .
    KIO-301 chloride hydrochloride
  • HY-P2162
    Kemptamide

    		Myosin Cancer
    Kemptamide, a 13 amino acid fragment with a sequence corresponding to residues 11-23 of gizzard light chain. Kemptamide is a peptide substrate of myosin light-chain kinase (MLCK) .
    Kemptamide
  • HY-P10204
    FZD7 antagonist 1

    		Wnt Cancer
    FZD7 antagonist 1 (peptide 34) is a dFz7-21 analogue. FZD7 antagonist 1 is an FZD7 antagonist that inhibits the wnt3a with IC50 value of 9.2 nM. FZD7 antagonist 1 blocks TcdB−FZD interaction via targeting FZD receptors .
    FZD7 antagonist 1
  • HY-133885
    S-(-)-7-Desmethyl-8-nitro blebbistatin

    		Drug Derivative Others
    S-(-)-7-Desmethyl-8-nitro blebbistatin (compound 12) is an analog of (-)-Blebbistatin (HY-13441). (-)-Blebbistatin is a selective non-muscle myosin II inhibitor .
    S-(-)-7-Desmethyl-8-nitro blebbistatin
  • HY-148516A
    (R)-MPH-220

    		Myosin Neurological Disease
    (R)-MPH-220 is the R isomer of MPH-220 (HY-148516). MPH-220 is a selective and orally active inhibitor of skeletal muscle myosin-2. MPH-220 enables muscle relaxation. MPH-220 is anti-spastic agent that can be used in the research of spasticity and muscle stiffness .
    (R)-MPH-220
  • HY-125957
    A-3 hydrochloride

    		PKA Casein Kinase CaMK PKC Others
    A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. It against PKA (Ki=4.3 µM), casein kinase II (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM). A-3 hydrochloride also inhibits PKC and casein kinase I with Ki values of 47 µM and 80 µM, respectively .
    A-3 hydrochloride
  • HY-148851
    Bacteriochlorophyll a, from Rhodopseudomonas sphaeroides (under argon)

    BChl a, from Rhodopseudomonas sphaeroides (under argon)

    		 Bacterial Others
    Bacteriochlorophyll a, from Rhodopseudomonas sphaeroides (under argon) (BChl a, from Rhodopseudomonas sphaeroides (under argon)) is a chlorophyll analog found in some bacteria that participates in the light absorption and energy transfer processes of photosynthesis .
    Bacteriochlorophyll a, from Rhodopseudomonas sphaeroides (under argon)
  • HY-176850
    Myosin-IN-2

    		Myosin Cardiovascular Disease
    Myosin-IN-2 (Example 16) is a Myosin ATPase inhibitor with a IC50 of 1.06  μM. Myosin-IN-2 can be used for heart diseases like hypertrophic cardiomyopathy (HCM) research .
    Myosin-IN-2
  • HY-P5998
    Myosin Light Chain Kinase Substrate (smooth muscle)

    		Myosin Cancer
    Myosin Light Chain Kinase Substrate (smooth muscle) is a smooth muscle myosin light chain kinase (MLCK) synthetic peptide substrate .
    Myosin Light Chain Kinase Substrate (smooth muscle)
  • HY-176914
    Myosin-IN-3

    		Ferroptosis Myosin Cardiovascular Disease Inflammation/Immunology
    Myosin-IN-3 (Compound 4-1) is a pyrimidine ketone derivative. Myosin-IN-3 exhibits significant anti ferroptotic activity (IC50 = 3.11 μM) while possessing myosin (IC50 = 3.09 μM) inhibitory activity and antioxidant activity (DPPH EC50 = 23.17 μM; MDA EC50 = 55.34 μM). Myosin-IN-3 can be used for research on heart conditions such as hypertrophic cardiomyopathy .
    Myosin-IN-3
  • HY-P10346
    smMLCK peptide

    Smooth-Muscle myosin light-chain Kinase (796-815)

    		 Myosin Cardiovascular Disease Inflammation/Immunology
    smMLCK peptide is a specific inhibitor of smooth muscle myosin light chain kinase (smMLCK). The smMLCK peptide mimics the substrate and competitively inhibits the binding of the actual substrate to the enzyme, thereby inhibiting the kinase activity. This inhibition prevents the phosphorylation of the myosin light chain, thus inhibiting muscle contraction .
    smMLCK peptide
  • HY-19133
    ME 3407

    EF-4040

    		 Na+/K+ ATPase Myosin PKA Metabolic Disease
    ME-3407 (EF-4040) is a H +-K +-ATPase redistribution disruptor and myosin light chain kinase (MLCK) and protein kinase A inhibitor. ME-3407 blocks gastric acid secretion and aminopyrine accumulation by inhibiting microsomal-to-apical membrane redistribution of H +-K +-ATPase and suppressing MLCK-mediated myosin light chain phosphorylation. ME-3407 is promising for research of peptic ulcer .
    ME 3407

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

  

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

  

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: